驱动癌症中18F-FDG蓄积的信号通路
18F-FDG PET测量葡萄糖消耗,是癌症管理的重要组成部分。大多数癌症类型上调葡萄糖消耗,导致癌细胞中18F-FDG PET蓄积升高。本文综述过去5年新发现的驱动癌症葡萄糖消耗的蛋白质和信号通路,并讨论当前对癌症葡萄糖消耗理解的局限性。
要点
- 18F-FDG蓄积的生化通路已明确,但激活葡萄糖转运体和己糖激酶的上游信号通路了解较少。
- 过去5年研究鉴定了驱动癌症葡萄糖消耗的新蛋白质和信号通路。
- 理解这些信号通路可能为18F-FDG PET扫描提供额外生物学见解并提示新用途。
核心结论
- 过去5年研究鉴定了驱动癌症葡萄糖消耗的新蛋白质和信号通路,理解这些通路可能为18F-FDG PET提供额外生物学见解并提示新用途。
研究设计与样本
- 综述,总结过去5年基于更早研究的新发现,讨论癌症葡萄糖消耗的当前局限性。
主要发现
- 大多数癌症类型上调葡萄糖消耗,导致癌细胞中18F-FDG PET蓄积升高。
- 除c-Myc、PI3K/PKB和HIF1α等已知调节因子外,癌细胞调节以激活葡萄糖转运体和己糖激酶从而驱动18F-FDG蓄积升高的蛋白质和信号通路了解较少。
局限性
- 作者指出当前对癌症葡萄糖消耗的理解存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-FDG measures glucose consumption and is an integral part of cancer management. Most cancer types upregulate their glucose consumption, yielding elevated 18F-FDG PET accumulation in those cancer cells. The biochemical pathway through which 18F-FDG accumulates in cancer cells is well established. However, beyond well-known regulators such as c-Myc, PI3K/PKB, and HIF1α, the proteins and signaling pathways that cancer cells modulate to activate the facilitated glucose transporters and hexokinase enzymes that drive elevated 18F-FDG accumulation are less well understood. Understanding these signaling pathways could yield additional biologic insights from 18F-FDG PET scans and could suggest new uses of 18F-FDG PET in the management of cancer. Work over the past 5 years, building on studies from years prior, has identified new proteins and signaling pathways that drive glucose consumption in cancer. Here, we review these recent studies and discuss current limitations to our understanding of glucose consumption in cancer.
引用
- Salas JR, Clark PM. Signaling Pathways That Drive 18F-FDG Accumulation in Cancer. J Nucl Med. 2022. PMID: 35241480. doi:10.2967/jnumed.121.262609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。